Blocklisting Interim Review
December 04 2008 - 4:56AM
UK Regulatory
Medgenics, Inc.
('Medgenics' or the 'Company')
Issue of options to Director and Block Listing interim review
4 December 2008
1. Name of company:
Medgenics, Inc.
2. Name of scheme:
Warrants and Options under the Company's Share Incentive Schemes
3. Period of return: From To
4 June 2008 3 December 2008
4. Number and class of securities not issued under the scheme at the beginning
of the period:
18,356,633 common shares of par value of US$0.01 each ("Common Shares")
5. Number of securities issued under scheme during period:
30,119
6. Balance under scheme of securities not yet issued at end of period:
18,326,514 Common Shares
7. Number and class of securities originally admitted and the date of admission:
20,818,683 Common Shares admitted under the block admission on 4 December 2007.
Following the above issues during the period the total number of Common Shares
in issue is 106,728,195. Following the expiration of the lock-in agreements on
4 December 2008 the percentage of shares not in public hands is 24.8 per cent.
There are no changes in the shareholders who hold more than three per cent. of
the issued share capital as previously announced.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900
Dr. Andrew L. Pearlman
Grayling Global (Financial PR, UK) Phone: +44 207 255 5406
Jonathan Shillington jonathan.shillington@uk.grayling.com
Alistair Scott
Blomfield Corporate Finance Limited (Nominated Adviser) Phone: +44 207 489 4500
James Pinner
Alan MacKenzie
SVS Securities plc (Broker) Phone: +44 207 638 5600
Peter Manfield
Ian Callaway
United States contacts:
Grayling Global (Investor Relations) Phone: +1 646 284 8472
Leslie Wolf-Creutzfeldt lwolf-creutzfeldt@hfgcg.com
Grayling Global (Media Relations) Phone: +1 646 284 9455
Ivette Almeida ialmeida@hfgcg.com
NOTES TO EDITORS:
Medgenics, Inc. is a clinical-stage biopharmaceutical company developing its
unique tissue-based Biopump platform technology to provide sustained-action
protein therapy for the treatment of a range of chronic diseases.
Medgenics currently has two products in development based on this technology:
* EPODURE - producing erythropoietin (EPO) to treat anemia
* INFRADURE - producing interferon-alpha (IFN-a) to treat hepatitis C
The Company has demonstrated proof of principle of the Biopump treatment
procedure in a clinical trial using a short-acting version of EPODURE in anemic
subjects. The Company announced positive initial results in its Phase I/II
clinical trial for its long-acting version of EPODURE, designed to produce and
deliver a therapeutic dose of EPO steadily for three to six months or more,
which commenced in August 2008. The Company plans to follow with a clinical
trial of INFRADURE in 2009.
Medgenics intends to develop its innovative products and bring them to market
via multiple strategic partnerships with major pharmaceutical and/or medical
device companies, starting with EPODURE and INFRADURE.
Beyond these, Medgenics plans to develop and/or out-license a pipeline of future
Biopump products targeting the large and rapidly growing global protein therapy
market, which is forecast to reach US $87 billion by 2010. Other potential areas
include multiple sclerosis (interferon-a), haemophilia (Factor XIII), paediatric
growth hormone deficiency (human growth hormone) and diabetes (insulin).
Founded in 2000, Medgenics is a US-incorporated company with major operations in
Misgav, Israel. Medgenics was admitted to AIM in December 2007 (AIM: MEDG).
www.medgenics.com
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, which include all statements
other than statements of historical fact, including (without limitation) those
regarding the Company's financial position, business strategy, plans and
objectives of management for future operations. These statements relate to
future events, prospects, developments and strategies. Forward-looking
statements are sometimes identified by their use of the terms and phrases such
as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning,
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or
the negative of such terms and other comparable terminology. All such forward-
looking statements are based on current expectations and are subject to risks
and uncertainties. Should any of these risks or uncertainties materialize, or
should any of the Company's assumptions prove incorrect, actual results may
differ materially from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these forward-looking
statements, which speak only as of the date made. The Company expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained herein to reflect any change in the
Company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based. As a result of these
factors, the events described in the forward-looking statements contained in
this release may not occur.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024
